ImmunoGen, Inc. Announces Conference Call at 8:00 am ET March 30, 2012 to Discuss Today’s Favorable Announcements about Trastuzumab Emtansine (T-DM1) and About IMGN901

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, today announced that it will host a conference call at 8:00 am ET on Friday, March 30, 2012 to discuss the two releases issued by the Company earlier today:

MORE ON THIS TOPIC